Galmed Pharmaceuticals (GLMD) Competitors $1.93 -0.10 (-4.93%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.98 +0.05 (+2.54%) As of 07/11/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLMD vs. TRIB, ATHA, BGXX, BCDA, EQ, SNSE, LPTX, BTAI, XFOR, and PHXMShould you be buying Galmed Pharmaceuticals stock or one of its competitors? The main competitors of Galmed Pharmaceuticals include Trinity Biotech (TRIB), Athira Pharma (ATHA), Bright Green (BGXX), BioCardia (BCDA), Equillium (EQ), Sensei Biotherapeutics (SNSE), Leap Therapeutics (LPTX), BioXcel Therapeutics (BTAI), X4 Pharmaceuticals (XFOR), and PHAXIAM Therapeutics (PHXM). These companies are all part of the "pharmaceutical products" industry. Galmed Pharmaceuticals vs. Its Competitors Trinity Biotech Athira Pharma Bright Green BioCardia Equillium Sensei Biotherapeutics Leap Therapeutics BioXcel Therapeutics X4 Pharmaceuticals PHAXIAM Therapeutics Galmed Pharmaceuticals (NASDAQ:GLMD) and Trinity Biotech (NASDAQ:TRIB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment. Do insiders and institutionals have more ownership in GLMD or TRIB? 76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are owned by institutional investors. 19.8% of Galmed Pharmaceuticals shares are owned by insiders. Comparatively, 8.2% of Trinity Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer GLMD or TRIB? In the previous week, Trinity Biotech had 1 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 2 mentions for Trinity Biotech and 1 mentions for Galmed Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 1.89 beat Trinity Biotech's score of 0.93 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Galmed Pharmaceuticals Very Positive Trinity Biotech Positive Do analysts rate GLMD or TRIB? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Trinity Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings & valuation, GLMD or TRIB? Galmed Pharmaceuticals has higher earnings, but lower revenue than Trinity Biotech. Trinity Biotech is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalmed PharmaceuticalsN/AN/A-$7.52M-$16.66-0.12Trinity Biotech$61.56M0.23-$31.79M-$2.93-0.27 Which has more risk & volatility, GLMD or TRIB? Galmed Pharmaceuticals has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Trinity Biotech has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Is GLMD or TRIB more profitable? Galmed Pharmaceuticals has a net margin of 0.00% compared to Trinity Biotech's net margin of -51.64%. Trinity Biotech's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Galmed PharmaceuticalsN/A -32.21% -28.59% Trinity Biotech -51.64%N/A -27.43% SummaryTrinity Biotech beats Galmed Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Galmed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLMD vs. The Competition Export to ExcelMetricGalmed PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.36M$2.74B$5.62B$9.10BDividend YieldN/A1.79%5.24%4.00%P/E Ratio-0.129.4228.0520.27Price / SalesN/A714.12429.5999.27Price / CashN/A165.3637.4658.16Price / Book0.204.608.055.49Net Income-$7.52M$31.26M$3.18B$250.45M7 Day Performance6.93%4.80%3.60%4.77%1 Month Performance19.88%5.42%4.03%7.66%1 Year Performance-47.32%-4.36%29.49%16.39% Galmed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLMDGalmed Pharmaceuticals1.4273 of 5 stars$1.93-4.9%N/A-46.4%$3.36MN/A-0.1220Positive NewsGap DownTRIBTrinity Biotech1.0058 of 5 stars$0.65-0.3%N/A-71.4%$11.77M$61.56M-0.23480ATHAAthira Pharma3.7979 of 5 stars$0.30+2.4%$11.25+3,625.2%-86.8%$11.52MN/A-0.1540Positive NewsGap UpBGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002Gap DownBCDABioCardia3.521 of 5 stars$1.95-9.3%$25.00+1,182.1%-23.5%$11.13M$60K-0.8440Positive NewsGap DownEQEquillium2.9264 of 5 stars$0.32+1.7%$3.00+851.8%-54.0%$11.07M$41.10M-0.8140News CoverageGap DownSNSESensei Biotherapeutics4.6719 of 5 stars$8.58-1.2%$90.00+949.0%-40.1%$10.94MN/A-0.3740Positive NewsGap DownLPTXLeap Therapeutics2.0863 of 5 stars$0.30+13.5%$3.38+1,036.7%-84.2%$10.84MN/A-0.1740Gap DownBTAIBioXcel Therapeutics4.2586 of 5 stars$1.81+2.3%$42.60+2,253.6%-89.7%$10.72M$2.27M-0.1390News CoveragePositive NewsXFORX4 Pharmaceuticals4.9408 of 5 stars$1.90+3.8%$72.33+3,707.0%-93.1%$10.59M$2.56M0.8980News CoveragePositive NewsHigh Trading VolumePHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049 Related Companies and Tools Related Companies TRIB Competitors ATHA Competitors BGXX Competitors BCDA Competitors EQ Competitors SNSE Competitors LPTX Competitors BTAI Competitors XFOR Competitors PHXM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLMD) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galmed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GLMD Stock Alerts